Axial Biotherapeutics is a clinical stage biopharmaceutical company harnessing the gut-brain axis to develop novel Central Nervous System (CNS) Therapeutics to improve the quality of life for people with CNS diseases and disorders.
Axial’s scientific co-founder, Sarkis K. Mazmanian, Ph.D., and researchers from the California Institute of Technology (Caltech) discovered a novel, causal link between the gut microbiome and Parkinson’s Disease (PD) and Autism Spectrum Disorder (ASD). In a PD mouse model, gut bacteria were shown to promote hallmark disease processes including motor and gastrointestinal (GI) dysfunction and inflammation of the nervous system resulting in alpha synuclein aggregation (both in the gut and brain). Further, colonization with microbiota from PD patients in PD mice enhances physical (motor and GI) impairments compared to microbiota transplants from healthy human donors. Evaluation of organisms and genes over-represented in the PD microbiome resulted in the identification of a druggable pathway that is sufficient to induce motor and GI symptoms and brain pathology in a validated disease model of PD.
In ASD, a human commensal bacterial therapy has shown to correct gut permeability, restore a healthy microbial composition and ameliorate core and non-core behavioral symptoms associated with ASD. In addition, Axial has developed a gut-selective, nonbacterial-based therapy that has shown to improve barrier integrity and ameliorate core and non-core behavioral symptoms associated with ASD.
The findings suggest that targeting the gut microbiome may provide a new approach for diagnosing and treating PD and ASD and potentially other CNS diseases.
Harnessing the Gut -Brain Axis to Treat Neurological Disorders
Axial Biotherapeutics, leader of a paradigm shift in treating CNS disorders, has taken a radical departure from conventional neuroscience with its approach that treats disease through the gut-brain axis. In recent years, studies suggest a significant impact of the gut microbiome in human health and disease. Axial’s focus is to develop gut-selective, best-in-class therapies to treat CNS-based disorders by targeting the GI.